Metformin and -cell function in insulin-treated patients with type 2 diabetes: A randomized placebo-controlled 4.3-year trial

Wiebe Top, Coen Stehouwer, Philippe Lehert, Adriaan Kooy*

*Bijbehorende auteur voor dit werk

    OnderzoeksoutputAcademicpeer review

    5 Citaten (Scopus)
    357 Downloads (Pure)


    In this trial, 390 insulin-treated patients with type 2 diabetes were randomized to either placebo or metformin. Fasting levels of glucose, insulin and C peptide were determined at baseline, after 4 months and yearly thereafter for 4 years to assess fasting estimates of beta cell function. The primary endpoint was the fasting C peptide-to-glucose ratio (FCPGR) and secondary measures were the disposition index (DI) and the fasting C peptide (FCP). We analysed the results with a general linear mixed model. Baseline FCPGR was 5.27 (95% CI, 4.83 - 5.71). Compared to placebo, FCPGR increased in the metformin group with 1.48 (95% CI, 1.09 - 1.87, P

    Originele taal-2English
    Pagina's (van-tot)730-733
    Aantal pagina's4
    TijdschriftDiabetes obesity & metabolism
    Nummer van het tijdschrift3
    StatusPublished - mrt.-2018

    Citeer dit